Joseph Thome
Stock Analyst at TD Cowen
(0.23)
# 4,220
Out of 4,893 analysts
18
Total ratings
21.43%
Success rate
-29.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Thome
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DRUG Bright Minds Biosciences | Initiates: Buy | n/a | $25.93 | - | 1 | May 13, 2025 | |
| VRDN Viridian Therapeutics | Initiates: Buy | n/a | $17.12 | - | 1 | Nov 25, 2024 | |
| UTHR United Therapeutics | Maintains: Buy | $350 → $400 | $300.16 | +33.26% | 2 | Oct 21, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | n/a | $15.38 | - | 1 | Jul 2, 2024 | |
| ALKS Alkermes | Initiates: Buy | $34 | $30.46 | +11.62% | 1 | Jun 17, 2024 | |
| PRME Prime Medicine | Initiates: Buy | n/a | $4.69 | - | 1 | Apr 8, 2024 | |
| MGX Metagenomi | Initiates: Outperform | n/a | $2.21 | - | 1 | Mar 5, 2024 | |
| PTCT PTC Therapeutics | Maintains: Market Perform | $32 → $30 | $49.51 | -39.41% | 2 | Mar 1, 2024 | |
| YMAB Y-mAbs Therapeutics | Downgrades: Market Perform | n/a | $4.53 | - | 1 | Jan 5, 2023 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | n/a | $32.98 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.35 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.46 | - | 1 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $130 | $110.73 | +17.40% | 2 | Jun 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $12.16 | - | 1 | Jan 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.76 | - | 1 | Nov 23, 2021 |
Bright Minds Biosciences
May 13, 2025
Initiates: Buy
Price Target: n/a
Current: $25.93
Upside: -
Viridian Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: n/a
Current: $17.12
Upside: -
United Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $350 → $400
Current: $300.16
Upside: +33.26%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: n/a
Current: $15.38
Upside: -
Alkermes
Jun 17, 2024
Initiates: Buy
Price Target: $34
Current: $30.46
Upside: +11.62%
Prime Medicine
Apr 8, 2024
Initiates: Buy
Price Target: n/a
Current: $4.69
Upside: -
Metagenomi
Mar 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $2.21
Upside: -
PTC Therapeutics
Mar 1, 2024
Maintains: Market Perform
Price Target: $32 → $30
Current: $49.51
Upside: -39.41%
Y-mAbs Therapeutics
Jan 5, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $4.53
Upside: -
Xenon Pharmaceuticals
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $32.98
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.35
Upside: -
Oct 10, 2022
Initiates: Outperform
Price Target: n/a
Current: $5.46
Upside: -
Jun 29, 2022
Maintains: Outperform
Price Target: $120 → $130
Current: $110.73
Upside: +17.40%
Jan 31, 2022
Initiates: Outperform
Price Target: n/a
Current: $12.16
Upside: -
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.76
Upside: -